EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat

Gema Vera, Laura López-Gómez iD, Rocío Girón iD, María Isabel Martín-Fontelles, Kulmira Nurgali iD, Raquel Abalo iD, José Antonio Uranga iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241914430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Gema Vera und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Health Sciences, Faculty of Health Sciences, University Rey Juan Carlos (URJC), 28922 Alcorcón, Spain. Hauptthemen laut MEDLINE: Visceral Pain, Mucositis, Neuralgia, Cannabinoids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Comunidad de Madrid, Universidad Rey Juan Carlos.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

5-fluorouracil (5-FU) is an antineoplastic drug used to treat colorectal cancer, but it causes, among other adverse effects, diarrhea and mucositis, as well as enteric neuropathy, as shown in experimental animals. It might also cause neuropathic pain and alterations in visceral sensitivity, but this has not been studied in either patients or experimental animals. Cannabinoids have antimotility and analgesic effects and may alleviate 5-FU-induced adverse effects. Our aim was to evaluate the effects of the cannabinoid agonist WIN 55,212-2 on neuropathic and visceral pain induced by a non-diarrheagenic dose of 5-FU. Male Wistar rats received a dose of 5-FU (150 mg/kg, ip) and gastrointestinal motility, colonic sensitivity, gut wall structure and tactile sensitivity were evaluated. WIN 55,212-2 (WIN) was administered to evaluate its effect on somatic (50–100 µg ipl; 1 mg/kg, ip) and visceral (1 mg/kg, ip) sensitivity. The cannabinoid tetrad was used to assess the central effects of WIN (1 mg/kg, ip). 5-FU decreased food intake and body weight gain, produced mucositis and thermal hyperalgesia, but these effects were reduced afterwards, and were not accompanied by diarrhea. Tactile mechanical allodynia was also evident and persisted for 15 days. Interestingly, it was alleviated by WIN. 5-FU tended to increase colonic sensitivity whereas WIN reduced the abdominal contractions induced by increasing intracolonic pressure in both control and 5-FU-treated animals. Importantly, the alleviating effects of WIN against those induced by 5-FU were not accompanied by any effect in the cannabinoid tetrad. The activation of the peripheral cannabinoid system may be useful to alleviate neuropathic and visceral pain associated with antitumoral treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Visceral PainMucositisNeuralgiaCannabinoidsHumansRatsMaleAnimalsRats, WistarCannabinoid Receptor AgonistsFluorouracilBenzoxazinesHyperalgesiaDiarrheaMorpholinesNaphthalenes

Stichwörter der Autor:innen

cancer chemotherapycannabinoidchemotherapy-induced adverse effectsgastrointestinal motor functionperipheral neuropathyvisceral pain

Substanzen

Cannabinoid Receptor AgonistsFluorouracilBenzoxazinesCannabinoids(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneMorpholinesNaphthalenes

Autor:innen und Institutionen

  • Department of Basic Health Sciences, Faculty of Health Sciences, University Rey Juan Carlos (URJC), 28922 Alcorcón, Spain.
  • High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut-URJC), University Rey Juan Carlos (URJC), 28922 Alcorcón, Spain.
  • Associated I+D+i Unit to the Institute of Medicinal Chemistry (IQM), Scientific Research Superior Council (CSIC), 28006 Madrid, Spain.
  • High-Performance Research Group in Experimental Pharmacology (PHARMAKOM-URJC), University Rey Juan Carlos (URJC), 28922 Alcorcón, Spain.
  • Institute for Health and Sport, College of Health and Biomedicine, Victoria University, Melbourne, VIC 3011, Australia.
  • Department of Medicine Western Health, University of Melbourne, Melbourne, VIC 3010, Australia.

ORCID-Profile: Laura López-Gómez, Rocío Girón, Kulmira Nurgali, Raquel Abalo, José Antonio Uranga

Förderung

  • Ministerio de Ciencia e Innovación
  • Comunidad de Madrid
  • Universidad Rey Juan Carlos

Zitieren

APA

Vera, G., López-Gómez, L., Girón, R., Martín-Fontelles, M. I., Nurgali, K., Abalo, R., & Uranga, J. A. (2023). Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914430

Vancouver

Vera G, López-Gómez L, Girón R, Martín-Fontelles MI, Nurgali K, Abalo R, et al. Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914430

BibTeX
@article{Vera2023,
  author = {Vera, Gema and López-Gómez, Laura and Girón, Rocío and Martín-Fontelles, María Isabel and Nurgali, Kulmira and Abalo, Raquel and Uranga, José Antonio},
  title = {Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241914430}
}
Kostenlos starten →